Evommune Inc

EVMN

Market cap $915M

The 70-patient trial was designed to evaluate the safety and efficacy of intravenous dosing of 5mg/kg on day 1 and day 28 (n=48 active, n=22 placebo) over 12 weeks.

IPO stock Evommune roughly doubled Tuesday on positive results for its intravenously infused eczema treatment.

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. This long-acting fusion protein consisting of an interleukin-18 (IL-18) binding protein and an anti-serum albumin Fab-associated domai.

Last year, the biotechnology industry leaned heavily into the power of artificial intelligence (AI), using machine learning models to identify drug targets, to optimize molecules, and to make key predictions about trial outcomes. Alongside the continued proliferation of technology within the drug development space, companies with a focus on obesity, rare diseases, and oncology applications saw commercial achievements.

PALO ALTO, Calif.--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. “The recent completion of our IPO puts us in a strong position to deliver on the years ahead, with three Phase 2 readouts across our two lead programs, EVO756 and EVO301, expe.

PALO ALTO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the pricing of its initial public offering of 9,375,000 shares of common stock at an initial public offering price of $16.00 per share.